ERBB2 and breast cancer: Furthermore, pretreatment with reovirus significantly enhanced the antitumor efficacy of subsequent T-BsAb therapy against the subcutaneous KPC (KrasG12D/+; Trp53R172H/+; Pdx1-Cre) tumor model and the orthotopic HER2-positive breast cancer model.